Skip to main content

Table 1 Baseline characteristics of 1502 HCC patients and patients with high and low FAR risk groups

From: Preoperative fibrinogen-to-albumin ratio predicts the prognosis of patients with hepatocellular carcinoma subjected to hepatectomy

Variables Total (n = 1502) Low FAR
(n = 1126)
High FAR
(n = 376)
P value
Age(years) 50 (43, 59) 50 (42, 59) 52 (45, 60) 0.017
Sex     0.242
Male 1291 (86.0) 961 (85.3) 330 (87.8)  
Female 211 (14.0) 165 (14.7) 46 (12.2)  
Positive HBsAg 1297 (86.4) 979 (86.9) 318(84.6) 0.246
Positive anti-HCV 22 (1.5) 18 (1.6) 4 (1.1) 0.455
Platelet count (109/L) 207 (160, 266) 192 (149, 243) 263 (211, 336)  < 0.001
Neutrophil count (109/L) 3.6 (2.8, 4.8) 3.3 (2.6, 4.4) 4.5 (3.6, 5.9)  < 0.001
Lymphocyte count (109/L) 1.7 (1.4, 2.2) 1.8 (1.4, 2.2) 1.7 (1.3, 2.1)  < 0.001
Monocyte count (109/L) 0.5 (0.4, 0.6) 0.4 (0.3, 0.6) 0.6 (0.4, 0.8)  < 0.001
Total bilirubin (μmol/L) 13.1 (9.7, 17.9) 13.2 (9.9, 17.8) 12.8 (9.4, 18.2) 0.615
Albumin (g/L) 39.4 (36.2, 42.4) 40.3 (37.4, 43.3) 35.9 (33.5, 39.2)  < 0.001
ALT (U/L) 35 (24, 50) 35 (24, 50) 34 (22, 54) 0.813
AST (U/L) 39 (29, 57) 37 (29, 54) 46 (32, 69)  < 0.001
Prothrombin time (s) 12.8 (12.0, 13.6) 12.7 (12.0, 13.6) 12.9 (12.2, 13.9) 0.106
Fibrinogen (g/L) 2.7 (2.2, 3.4) 2.5 (2.1, 2.9) 4.0 (3.5, 4.7)  < 0.001
Child–Pugh grade      < 0.001
A 1401 (93.3) 1076 (95.6) 325 (86.4)  
B 101 (6.7) 50 (4.4) 51 (13.6)  
AFP ( ng/mL)     0.449
 ≥ 400 638 (42.5) 472 (41.9) 166 (44.1)  
 < 400 864 (57.5) 654 (58.1) 210 (55.9)  
FAR 6.9 (5.5, 8.9) 6.2 (5.2, 7.3) 10.9 (9.6, 13.1)  < 0.001
NLR 2.1 (1.5, 3.0) 1.9 (1.4, 2.5) 2.9 (2.0, 4.1)  < 0.001
PLR 115.7 (85.4, 160.6) 104.6 (79.5, 141.7) 157.0 (116.3, 210.5)  < 0.001
MLR 0.3 (0.2, 0.4) 0.2 (0.2, 0.3) 0.3 (0.3, 0.5)  < 0.001
SII 422 (262, 682) 354 (229, 543) 744 (485, 1156)  < 0.001
CSPH 136 (9.1) 111 (9.9) 25 (6.6) 0.060
Ascites 169 (11.3) 106 (9.4) 63 (16.8)  < 0.001
Cirrhosis 680 (45.3) 527 (46.8) 153 (40.7) 0.039
Tumour size      < 0.001
 > 5 883 (58.8) 570 (50.6) 313 (83.2)  
 ≤ 5 619 (41.2) 556 (49.4) 63 (16.8)  
Tumour number     0.035
Multiple 288 (19.2) 202 (17.9) 86 (29.9)  
Single 1214 (80.8) 924 (82.1) 290 (77.1)  
MVI 393 (26.2) 241 (21.4) 152 (38.7)  < 0.001
BCLC stage      < 0.001
0 53 (3.5) 51 (4.5) 2 (0.5)  
A 785 (52.3) 633 (56.2) 152 (40.4)  
B 257 (17.1) 192 (17.1) 65 (17.3)  
C 407 (27.1) 250(22.2) 157 (41.8)  
Blood loss (mL)      < 0.001
 ≥ 400 541 (36.0) 366 (32.5) 175 (46.5)  
 < 400 961 (64.0) 760 (67.5) 201 (53.5)  
Blood transfusion 198 (13.2) 123 (10.9) 75 (19.9)  < 0.001
Extent of resection      < 0.001
Major hepatectomy 754 (50.2) 513 (45.6) 241 (64.1)  
Minor hepatectomy 748 (49.8) 613 (54.4) 135 (35.9)  
  1. Continuous data are show as median (25th–75th interquartile range) and categorical data are expressed as n (%)
  2. HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; ALT, Alanine aminotransferase; AFP, alpha-fetoprotein; FAR, fibrinogen-albumin ratio; NLR, neutrophil–lymphocyte ratio; MLR, monocyte-lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic immune–inflammation index; CSPH, clinically significant portal hypertension; MVI, macrovascular invasion; BCLC, Barcelona Clinical Liver Cancer